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Abstract

Purpose: We performed an epidemiological study of orbital lymphoma in the United
States to determine how histological subtypes confer differing prognosis, and understand
other factors associated with survival.

Methods: All patients in the Surveillance, Epidemiology and End Results database
diagnosed with a histologically confirmed orbital lymphoma between 1973 and 2014
were included. Exclusion criteria included diagnosis at autopsy and the presence of other
malignancies. Measures included patient demographic information, histological subtype
and treatment modalities. Outcomes included overall and disease specific survival.

Results: Of the 1504 cases identified, 702 were male (46.7%, mean age: 64.4 years,
standard deviation [SD]: 15.3) and 802 were female (53.3%, mean age: 67.5 years, SD:
14.3). Mucosal associated lymphoid tissue (MALT) (49.5%) and diffuse large B cell
lymphoma (DLBCL) (19.5%) were the two most common histologic subtypes. MALT
lymphoma conferred the best prognosis (10-year cancer specific survival [CSS] 90.2%,
95% Confidence Interval [CI] 87.4% – 93.1%) and DLBCL conferred the worst
prognosis (10-year CSS 68.6%, 95% CI 62.5% – 75.3%) (p<0.001, log-rank test). Older
age above 50 (Hazard Ratio [HR]: 3.71, 95% Confidence Interval [CI]: 2.94-4.66,
p<0.001), male sex (HR: 1.22, 95% CI: 1.039-1.441, p = 0.015), no radiation (HR: 1.72,
95% CI: 1.46-2.02, p<0.001) and DLBCL histology were significant predictors of worse
overall survival.

Conclusions: DLBCL histology confers the worst outcomes whereas MALT lymphoma
confers the best outcome in orbital lymphoma. Age, gender, and radiation treatment also
influence survival. These epidemiological results can be used clinically to communicate
outcomes on the basis of patient characteristics and disease histology.
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Introduction
Orbital lymphoma (OL) accounts for the majority of orbital malignancies in
adults.1,2 However, it is still a rare disease, accounting for less than 1% of all NonHodgkin’s Lymphoma (NHL).3 Due to its rarity, efforts to document its presentation and
epidemiology have relied primarily on case reports or cohorts of patients pooled from
around the world.2,4–11 Although, conjunctival and ocular adnexal lymphoma are thought
to be along the same spectrum as OL, the prognosis of purely conjunctival lymphoma
tends to be better.4

It has been observed that the various histologic subtypes of OL confer different
overall survival rates.4,10–12 In the largest study reporting the effect of histologic subtype
of OL on survival, Olsen et al found extranodal marginal zone B cell lymphoma (which is
also known as Mucosa Associated Lymphoid Tissue [MALT] lymphoma) to confer the
best prognosis and mantle cell lymphoma (MCL) to confer the worst prognosis in a
cohort of 797 patients from seven international cancer centers.11 However, patients in the
United States accounted for only 30% of their cohort and were included from only three
regional cancer centers. Moreover, no subgroup analysis was performed in their study for
survival amongst the American cohort. Although prognostication is of great importance
in oncologic care, due to the rarity of this disease in the United States, there is no large
study that provides prognostication by histological type of the disease. Although disease
staging can currently offer prognostic value it is not as predictive of survival in OL as
disease histology.10 Further survival data based off disease histology could offer more
information to prognosticate with.
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Background
Early History
The earliest mention of “orbital lymphoma” in PubMed indexed journals dates
back to 1965, when Jortay described a case of unilateral exophthalmos that was thought
to be a chronic granuloma or orbital lymphoma.13 Reese et al in 1971 also identified
orbital lymphomas compromising 10% of the 504 primary orbital tumors in their study
whereas Henderson et al in 1974 diagnosed orbital lymphomas comprising 8% of their
series of 465 orbital tumors. In Henderson’s studies, orbital lymphoma was seen in
patients mostly younger than 20.14

In 1978, Jakobiec and colleagues from the Harkness Eye Institute at ColumbiaPresbyterian Medical Center published a review of lymphoid lesions of the orbit,
identifying 13 orbital lymphomas from 410 cases of orbital lymphoid lesions
accumulated over 40 years in their pathology laboratory.15 They noted that the disease
was more commonly occurring in older adults above the age of 50. Furthermore, they
noted that the diagnosis and prognosis of these lesions was challenging for the clinician
and the pathologist because of difficulty in identifying frankly neoplastic cellular details
in the lesions and discerning whether the orbital lesion is primary or a manifestation of
systemic diseases. In 8 of the 13 patients with initially presumed primary orbital
lymphoma, metastasis to other sites was usually found at the time of diagnosis, with all
cases having metastasized within 1 year and 3 months of initial diagnosis. Treatment of
the disease involved radiotherapy with 2000-5000 rads (equivalent to 20-50 Gy),
exenteration in some cases and systemic chemotherapy reserved for treatment resistant
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tumors. Survival from time of diagnosis ranged from 5 months to 6 ½ years – the cause
of death in all patients was directly related to the tumor or the side effects of treatment.15

Disease Histopathologic Classifications
WHO Classification
Lymphomas are malignancies due to abnormal clonal proliferation of
lymphocytes. Although there have been many classification systems in the past for
lymphomas (which are covered later in this thesis), the most updated system is the WHO
classification, which was majorly updated in 2016.16 In this classification, lymphomas
can be divided into Hodgkin’s lymphoma, which consists of B-cells and Non-Hodgkin’s
lymphoma which includes B-Cell, T-Cell and rarely NK cell lymphomas. These types
can be further subdivided based on histo-cytologic criteria.10 There are over 40 subcategorizations, many of which are beyond the scope of this study due to the rarity of
their occurrence in the orbit (for more information, see Caponetti and Bagg 2017).17 In
particular, this thesis focuses on Non-Hodgkin B-Cell lymphomas – for more information
on T cell lymphomas and beyond, see Olsen et al 2019, which is referenced in this
thesis.10

In the orbit, the following histological subtypes of NHL are frequently
encountered: follicular lymphoma (FL - International Classification of Diseases for
Oncology 3 [ICD-O-3]: 9695/3, 9690/3, 9691/3, 9698/3), extranodal marginal zone
lymphoma of mucosal associated lymphoid tissue (MALT - ICD-O-3: 9699/3), diffuse
large B cell lymphoma (DLBCL - ICD-O-3: 9680/3, 9684/3), lymphoplasmacytic
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lymphoma (LPL - ICD-O-3:9671/3), small lymphocytic lymphoma (SLL - ICD-O-3:
9670/3) and mantle cell lymphoma (MCL - ICD-O-3: 9673/3). Figure 1 demonstrates
how these histological subtypes are categorized.

Follicular lymphomas (FL) are of B cell lineage that demonstrate follicular
architecture. These follicles are uniform, densely packed to the point that they often
obliterate nodal architecture. They are composed of proportions of small cleaved cells
and some large cells that may or may not be cleaved. Grading of the lymphoma is based
on the proportion of large cells, as seen in table 1. Disease staging is not based on
histopathologic features but rather the Ann Arbor or AJCC Staging system, which will be
discussed later.18

FL
SLL

Non-Hodgkins Lymphoma

Small cell

MCL

LPL
Immature

MZL

MALT

B-Cell
Mature

Large cell

DLBCL

T-Cell
Plasma cell
Other

Figure 1:WHO Classification of Non-Hodgkin Lymphomas. Grey boxes indicate histological types not found commonly
in the orbit. Red indicates common orbital lymphoma histologies. FL=Follicular Lymphoma, SLL = Small Lymphocytic
Lymphoma, MCL = Mantle Cell Lymphoma, LPL = Lymphoplasmacytic Lymphoma, MZL = Marginal Zone
Lymphoma, MALT = Mucosa Associated Lymphoid Tissue Lymphoma, DLBCL = Diffuse Large B Cell Lymphoma
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Histopathologic Grade of Follicular Lymphoma
1
2
3

% of Large Cells
Under 25
25-50
Over 50

Table 1: Histopathologic Grading of Follicular Lymphomas

Marginal Zone Lymphomas are composed of small B lymphocytes with pale
cytoplasm known as monocytoid cells. They have an affinity for mucosal sites, hence the
designation of the specific subtype MALT lymphoma. These neoplastic cells may involve
marginal zones of reactive follicles and colonize adjacent follicles. There is no consensus
grading criteria for MALT lymphoma, but it is generally considered a ‘low grade’
neoplasm. Staging is based on the Ann Arbor criteria or the AJCC criteria.18

Small Lymphocytic Lymphoma, also known as chronic lymphocytic leukemia
when identified in non-solid tumor form, is a neoplasm made of mostly small round B
cells. Diagnostic criteria includes effacement of nodal architecture by sheets of small B
lymphocytes, pseudo-follicular proliferation. There is no consensus grading criteria for
this disease, but it is generally considered as a ‘low-grade’ neoplasm. Staging is based on
the Ann Arbor criteria or the AJCC criteria.18

MCL is a B cell neoplasm containing small to medium sized cells with mild or
moderate nuclear irregularities. The neoplasm commonly involves and expands the
mantle zone and compressing the germinal center in a lymph node. A key feature of this
subtype is its genetic expression of bcl1, which is discussed in the section on disease
pathogenesis. There is no consensus grading criteria for MALT lymphoma, but it is
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generally considered a ‘high grade’ neoplasm. Staging is based on the Ann Arbor criteria
or the AJCC criteria.18

LPL is a B cell neoplasm composed of small round B cells that display prominent
plasmacytoid differentiation. These cells also lack defining features of other small B cell
lymphomas. Many cases can express IgM and cause hyper-viscosity syndromes. There is
no consensus grading criteria for this neoplasm, though it is generally regarded as ‘lowgrade’. Staging is based on the Ann Arbor criteria or AJCC criteria.18

DLBCL is an aggressive neoplasm that consists of large cells that show a diffuse
pattern of growth that effaces normal nodal architecture. Although there are no formal
consensus grading criteria, it is considered ‘high grade.’ Staging is based off Ann Arbor
criteria or AJCC criteria.

Older Classifications
The Rappaport classification was amongst the earliest modern classifications used
to describe lymphomas and was proposed in 1956. Henry Rappaport and colleagues
argued for a clinically useful classification that was accurate, reproducible, easily taught
and learned. Using these principles, they classified NHL into two subtypes: nodular, in
which the neoplasm retained nodal architecture, and diffuse, which was characterized by
effacement of the lymph node architecture.19 Furthermore, they subclassified neoplasms
as ‘well-differentiated’, ‘poorly-differentiated’, and ‘histiocytic.’ This classification fell
out of favor with the realization that all lymphomas were of lymphoid and not histiocyte
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origin and the improvements in technology allowing for differentiate of B cell neoplasms
from other lymphoid cells.

In 1974 Lukes and Collins proposed the first classification based on cellular
origin and lymphocyte transformation alterations. This system did not consider cellular
architecture but introduced terms to describe individual cells such as small and large,
cleaved and uncleaved cells.

The Kiel Classification also built on the Lukes and Collins Classification and
divided neoplasms into low- and high-grade variants based on cell maturity. This
classification was updated extensively in 1988 and is shown in table 2.19

B Cell

T Cell

Low Grade
Lymphocytic- chronic lymphocytic and hairy cell
leukemia
Lymphoplasmacytic/cytoid
Plasmacytic
Centroblastic/centrocytic
Centrocytic
High Grade
Centroblastic
Immunoblastic
Large cell anaplastic
Burkitt lymphoma
Lymphoblastic
Rare types

Low Grade
Lymphocytic – chronic lymphocytic and
prolymphocytic leukemia
Lymphoepithelioid
Angioimmunoblastic
T zone
Pleomorphic, small cell
High Grade
Pleomorphic, medium and large cell
Immunoblastic
Large cell anaplastic
Lymphoblastic
Rare Types

Table 2: Updated Kiel Classification (1988)

In 1994, the International Lymphoma Study Group devised a consensus list of
lymphoid neoplasms, which were published as the ‘Revised European-American
Classification of Lymphoid Neoplasms’ (REAL). This classification utilized a
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combination of morphologic, immunophenotype, genetic and clinical features to classify
diseases as opposed to previous methods which insisted on just one ‘gold standard’
feature to guide classifications. These guidelines were thereafter modified slightly to
produce the current WHO classification.19

Of note, since these various older classifications were based off different
techniques and utilized different ‘gold standards,’ converting disease classifications from
older case reports and databases is often not possible due to the lack of information
available in those cases to reclassify the disease based on newer methods such as
immunohistochemistry, genetics, and protein expression.

Disease Pathogenesis
Although lymphomas most often occur within lymph nodes, they can manifest
extranodally in the conjunctiva, eyelids, lacrimal glands and the orbit. The pathogenesis
of orbital lymphomas can be categorized into three main mechanisms: genetic
abnormalities, autoimmune disorders and immunosuppressive disorders.

Genetic Abnormalities
MALT lymphoma of the orbit is associated with well described genetic
abnormalities. At the chromosomal level, trisomy 3, 7, 12 and 18 as well as translocations
t(11;18), q(21;21), t(1;14) (p22;q32), t(1;2), (p22;q12), t(14;18) (q32;q21), and t(3;14)
(p14.1;q32) have been described in MALT lymphomas isolated from the ocular adnexa.10
Most of these translocations affect cellular regulation and, in many cases, lead to the
eventual activation of nuclear factor kB (NF-kB). This gene codes for a transcription
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factor that is involved in immunologic signaling and is associated with numerous
lymphoid malignancies. The A20 gene is a repressor of NF-kB and is also found to be
downregulated in orbital lymphomas.10

DLBCL is also often associated with similar mutations in genes that lead to NFkB activation downstream. Notably, this histology is also associated with overproduction
of the anti-apoptotic protein bcl2, in particular due to the mutation t(14;18) (q32,q21),
which is found in up to 34% of cases. This mutation is also found in FL which may
account for some FLs transforming into DLBCLs.10 Other mutations associated with this
subtype include translocations of MYC, EZH2, BCL6, and MEF2B genes, which are well
known genes in tumorigenesis.

MCL is characterized by the hallmark translocation mutation of
t(11;14)(q13;q32). This leads to overproduction of the cellular proliferation factor Cyclin
D-1.

Other histological subtypes of orbital lymphomas also have many unique
mutations, however, their role in disease pathogenesis is not fully understood and is still
being actively studied.

Autoimmune Disorders
Autoimmune phenomena is commonly associated with lymphoproliferative
disorders and is a complex bidirectional process of active study.20 Many lymphomas
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present with paraneoplastic autoimmune diseases in addition to many autoimmune
diseases preceding the onset of a lymphoproliferative disorder. In Non-Hodgkin’s
Lymphoma (NHL), 70% of autoimmune diseases precede the onset of lymphoma. The
major theory relating the two diseases asserts that there are common underlying genetic
mutations that may drive unregulated proliferation of immune cells that are self-reactive
and/or malignant.20 Increased risk of NHL of the orbit, especially DLBCL and MALT
lymphoma, is reported in patients suffering from Sjogren’s syndrome, systemic lupus
erythematosus, rheumatoid arthritis, Hashimoto’s thyroiditis, immune thrombocytopenic
purpura, and autoimmune hemolytic anemia. In one case of orbital MALT lymphoma,
treatment of the autoimmune disease with methotrexate led to resolution of the
lymphoma without any further treatment.21

Immunosuppressive Disorders
There is a well-established relationship between lymphomas and
immunosuppressive states. Lymphoma is the most common cancer in patients infected
with human immunodeficiency virus – in particular DLBCL manifests with a high
frequency in this patient population.10 Furthermore, with treatment of the
immunosuppression, in particular with the introduction of highly active antiretroviral
therapy (HAART), the incidence of lymphoma has declined amongst patients with HIV.10
Although the mechanism underlying this association is not well known, increased viremia
amongst immunosuppressed patients, particularly with oncogenic viruses like Ebstein
Barr Virus (EBV) may play a role in pathogenesis. Orbital lymphoma has also been seen
in transplant patients as a rare manifestation of post-transplant lymphoproliferative
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disorder. This form of the disease is treated with reduced immune suppression in addition
to standard therapy.22

Clinical Features
Demographics
OL is a disease that primarily affects elderly patients. Though there are
differences amongst the age distribution for various histological subtypes of the disease,
73% of patients diagnosed with OL are over the age of 50.10 Notably, however, the age
distribution of DLBCL is wider than other histological subtypes, with 20% of patients
aged 40-49 years and 10% of patients aged younger than 40 years.

Although many case reports of orbital lymphoma in the past did not specify sex,
in a recent multicenter retrospective study by Olsen et al, the authors noted no major
difference in sex by histology with a roughly equal proportion of males and females. A
notable exception to this was the MCL cohort, where men composed 73% of the cases.11
Previous studies, although limited by their sample size, also observed a female
preponderance in MALT lymphoma and FL, in addition to the male preponderance in
MCL cases.

Presenting Symptoms
Patients with orbital lymphoma present with various complaints, the most
common of which is proptosis. Other symptoms include swelling, ptosis, diplopia,
limited extraocular movement, pain, change in vision, erythema, chemosis, and B-
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symptoms (fever, weight loss, night sweats).10 Unilateral proptosis is especially
concerning for an orbital tumor and should necessitate further imaging studies.
Duration
The duration of symptoms before formal ophthalmological consultation and
diagnosis varies widely based on the histological type of tumor. Low grade tumors tend
to present late, with MALT, FL, and CLL having a mean duration of symptoms of 6.5, 24
and 18 months respectively.10 By contrast, DLBCL has a duration of symptoms to
consultation of weeks. However, some higher-grade lymphomas such as MCL have
longer duration of symptoms up till 9 months until consultation is sought, implying
slower growth. Sometimes, these patients may be initially treated with antibiotics for
cellulitis, further delaying the diagnosis of lymphoma.

Location
Most NHL lymphomas of the ocular adnexa present as a unilateral tumor. The
exception to this is MCL, which presents bilaterally in 43% of patients and CLL, which
presents bilaterally in 50% of cases.10

In terms of location within the orbit, tumors can either be extraconal or intraconal
and can involve the extraocular muscles. Some tumors can involve more than one site.
See Figure 2 for a schematic explanation of extraconal vs. intraconal. Most B cell
lymphomas are located in the extraconal space (72%) and a majority of these involve the
lacrimal glands as well (51%). 8% of tumors are in the intraconal space and 9% involve
the extraocular muscles.10
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Figure 2: Extraconal versus intraconal orbital lesions. Image courtesy of Martins et al. "Microsurgery of the Orbit:
The Rule of Seven." Anatomy Research International. 2011 [Creative commons license]

Tumors can be defined as primary lymphoma or secondary lymphoma. By
definition, a tumor is primary if it is biopsy verified and the patient has no evidence of
concurrent lymphoma in another site or any history of lymphoma. If a patient has
evidence of distant neoplasms or a history of lymphoma, their OL is classified as
secondary. 73% of B-cell lymphomas arise as primary tumors. MALT and FL are more
likely to arise as primary tumors in the orbit whereas a large percentage of DLBCL and
MCL manifest as secondary orbital tumors (42% and 41% respectively).10 Furthermore,
DLBCL has a predilection to involve the periorbital bone whereas MALT lymphoma and
FL are more likely to involve the conjunctiva (40% and 38% of cases respectively).10

Disease Diagnosis and Workup
A full ophthalmologic evaluation alongside a complete physical examination is
warranted whenever an orbital mass is suspected. If examination findings points towards
an orbital tumor, imaging preferably with magnetic resonance imaging or a computed
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tomography scan of the orbits is indicated. If a tumor is identified on imaging, an open
biopsy is indicated for diagnostic confirmation.10 A fine needle biopsy is recommended
against, since it may not produce an adequate sample in which nodal architecture is
apparent.10

Histopathologic examination of the biopsy sample focuses on morphology,
immunohistochemical properties and protein expression studies. These are undertaken to
differentiate B-cell lymphomas from other rarer neoplasms, as well as identify specific
histological subtypes of the disease.10

Disease Staging
Although the Ann Arbor staging criteria was originally designed for Hodgkin’s
lymphoma, it is also very commonly used for staging NHL as well. There are 4 stages,
which are determined by assessing lymph node and extra-nodal involvement (single node
[or extra-nodal site] = stage I [I E], more than one node [or >1 extra-nodal site] = stage II
[II E]), involvement on one or both sides of the diaphragm (if both sides involved = stage
III) and disseminated metastasis (stage IV). This system is not very prognostically useful
for orbital lymphomas since the orbit counts only as 1 extra-nodal site, leading to the vast
majority of orbital lymphomas to be classified as stage I E, regardless of how locally
aggressive the disease is.10

In response to this issue, in 2009 the Ophthalmic Oncology Task Force of the
American Joint Committee on Cancer (AJCC) devised a new staging system for ocular
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adnexal lymphomas, that was based off the TNM staging criteria and allowed for finer
delineation and better prognostication of orbit specific lymphomas. This system is
outlined in table 3.

Even though this updated staging system allowed for better prognostication and
classification of the vast majority of OL patients previously classified as Ann Arbor
Stage I E, patient disease free survival and recurrence were more closely related to the
histopathological subtype rather than the tumor size or site-specific location, as outlined
by the TNM stage.23,24
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Primary Tumor (T)
• TX: lymphoma extent not specified
• T0: no evidence of lymphoma
• T1: lymphoma involving the conjunctiva alone without orbital involvement
• T1a: bulbar conjunctiva alone
• T1b: palpebral conjunctiva, +/- fornix, +/- caruncle
• T1c: extensive conjunctival involvement
• T2: lymphoma with orbital involvement +/- any conjunctival involvement
• T2a: anterior orbital involvement (+/- any conjunctival involvement)
• T2b: anterior orbital involvement (+/- any conjunctival involvement but with lacrimal
involvement)
T2c: posterior orbital involvement (+/- any conjunctival involvement, +/- anterior involvement,
+/- any extraocular muscle involvement)
• T2d: nasolacrimal drainage system involvement (+/- conjunctival involvement but not including
nasopharynx)
T3: lymphoma with preseptal eyelid involvement (infiltrates preseptal tissues such as dermis or
orbicularis muscle of anterior eyelid skin) +/- orbital involvement, +/- any conjunctival involvement
T4: orbital adnexal lymphoma extending beyond orbit to adjacent structures such as bone and brain
• T4a: involvement of nasopharynx
• T4b: osseous involvement (including periosteum)
• T4c: involvement of maxillofacial, ethmoidal or frontal sinuses
• T4d: intracranial spread

•

•
•

Regional Lymph Nodes (N)
• NX: involvement of lymph nodes not assessed
• N0: no evidence of lymph node involvement
• N1: involvement of ipsilateral regional lymph nodes
• N2: involvement of contralateral or bilateral regional lymph nodes
• N3: involvement of peripheral lymph nodes not draining ocular adnexal region
• N4: involvement of central lymph nodes
Note: regional lymph nodes include preauricular (parotid), submandibular and cervical

Distant Metastasis (M)
• M0: no evidence of involvement of other extranodal sites
• M1a: noncontiguous involvement of tissues or organs external to the ocular adnexa (e.g. parotid glands,
•
•

submandibular gland, lung, liver, spleen, kidney, breast, etc.)
M1b: lymphomatous involvement of the bone marrow
M1c: both M1a and M1b involvement

Table 3: AJCC Staging Guidelines for Ocular Adnexal Lymphomas 7th Edition

Treatment
The treatment of OL is coordinated by a multidisciplinary team including an
ophthalmologist, a hematologist and a radiation oncologist. Due to significant variation in
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disease progression based on histology, tumor site, and patient risk factors, treatment is
highly individualized for each patient.10

Radiation therapy (RT) is the mainstay of treatment for most localized, low-grade
OLs. RT can be used to eradicate the tumor or decrease tumor site prior to surgical
excision. In patients with high grade lymphomas, RT may be used in conjunction with
systemic chemotherapy to control the disease. In patients with MALT lymphoma RT is
used as monotherapy in 70% of cases.10 Radiation doses vary based on various factors,
but most patients are treated using a total dosage ranging between 20-54 Gy, delivered in
small fractions of 2 Gy. This therapy historically received excellent local control in over
90% of patients.10 Recently, there has been a push to decrease the total amount of
radiation in indolent lymphomas to 4 Gy in 2x2 Gy fractions due to evidence indicating
that excellent local control can be achieved with lower doses.25 Ocular side effects of
high dose radiation to the orbit include cataracts, cutaneous reactions,
keratoconjunctivitis sicca, and retinopathy.10

Chemotherapy is often used for OLs when the disease is either high grade (such
as in DLBCL or MCL) and/or is disseminated. Combination regimens include CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone), hyper-CVAD
(cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and
cytarabine) and CVP (cyclophosphamide, vincristine, and prednisone).10
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Immunotherapy is an emerging modality in the treatment of OLs. The anti-CD20
antibody Rituximab is commonly used in treating B cell lymphomas by preventing
cellular proliferation, activation, differentiation and signal transduction. Since its
introduction in the 1990s, Rituximab has significantly improved outcomes in lymphomas
– in OLs, the combination of Rituximab and chemotherapy is associated with improved
outcomes in patients with FL, MCL, and DLBCL.10

Prognosis
Collecting accurate data on long term prognosis in OL is challenging due to the
rarity of the disease and a paucity of long-term follow-up studies of patients. To date, the
patient’s histological subtype of OL is the most important prognostic factor. Lower grade
histologies such as MALT lymphoma show excellent remission rates of 100/120 patients
in a large cohort study, whereas higher grade histologies have worse remissions of 26/33
patients. Furthermore, in these patients, long term survival data was not available.10 In the
largest retrospective cohort study of OL conducted by Olsen and colleagues, 797 patients
from 7 eye centers globally were included. Their analysis showed that MALT and FL
lymphoma had much better long term prognosis (10 year disease specific survival of 92%
and 71% respectively) compared to the more aggressive DLBCL and MCL histologies
(10 year disease specific survival of 41% and 32% respectively).11

Statement of Purpose
The purpose of this thesis project is to elucidate prognostic factors in OL using
the Surveillance, Epidemiology and End Results (SEER) database. In doing so, the aim is
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to provide better prognostication data for patients suffering from this disease using the
largest ever cohort of patients with orbital lymphoma studied to date in the United States.

Specifically, the three main objectives of this study are:
1. Describe the epidemiology of OLs across various histologies in the United States
2. Determine overall and disease specific survival amongst various OL histologies
3. Determine whether other factors related to patient demographics or treatment
affect prognoses

We hope that our research will facilitate understanding the epidemiology and
outcomes of this rare disease and can help physicians communicate disease prognoses
more accurately and in an evidence-based manner to their patients depending on the
subtype of disease they have.

Methods
Database and Disease Coding
We determined our study population by searching the November 2016 submission
of the SEER database for all cases of Extranodal Non-Hodgkin’s Lymphoma in the orbit
(International Classification of Diseases 10 diagnosis code: C69.6). SEER first began
collecting data on cancer cases on January 1, 1973, in Connecticut, Iowa, New Mexico,
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Utah, and Hawaii and the metropolitan areas of Detroit and San Francisco-Oakland.
Since then, it has gradually increased its coverage and has included Seattle, Atlanta, Los
Angeles, Alaska, rural Georgia, Kentucky, Louisiana and New Jersey. Overall, the
geographic coverage of the database accounts for 27.8% of the overall US population.27

The following histologic subtypes were queried: follicular lymphoma (FL - ICDO-3: 9695/3, 9690/3, 9691/3, 9698/3), extranodal marginal zone lymphoma of mucosal
associated lymphoid tissue (MALT - ICD-O-3: 9699/3), diffuse large B cell lymphoma
(DLBCL - ICD-O-3: 9680/3, 9684/3), lymphoplasmacytic lymphoma (LPL - ICD-O3:9671/3), small lymphocytic lymphoma (SLL - ICD-O-3: 9670/3) and mantle cell
lymphoma (MCL - ICD-O-3: 9673/3). Cases were diagnosed between January 1st, 1973
and December 31st, 2014. Cases diagnosed at autopsy, or those that presented with
multiple neoplasms were excluded.

Study Variables
Data on survival, outcome, surgical procedure, radiation therapy, chemotherapy,
age at diagnosis, sex, and race were queried. Data on Ann-Arbor staging and TNM
staging was sparse in the database and thus not included. Surgical procedures were
grouped as follows: no surgery performed (SEER codes: 00), Unknown/other (SEER
codes: 90,99,27,13,10,14), or orbitotomy with biopsy (SEER codes:
20,22,23,24,25,26,27,30,41,50,60). For specifics on SEER procedure codes, see table 4.
Radiation therapy and chemotherapy was grouped into ‘yes’ and ‘no/unknown.’ Of note,
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the SEER database did not provide information on the specific types, dosages or
durations of chemotherapy or radiation.

SEER
Code
00
10
11
12
13
14
20
26
27

21
22
23
24
25
30
40
41
50
60
90
99

Explanation
None; no surgery of primary site; autopsy ONLY
Local tumor destruction, NOS
Photodynamic therapy
Electrocautery
Cryosurgery
Laser
Local tumor excision, NOS
Polypectomy
Excisional biopsy
Any combination of 20 or 26-27 WITH
Photodynamic therapy
Electrocautery
Cryosurgery
Laser ablation
Laser excision
Simple/partial surgical removal of primary site
Total surgical removal of primary site; enucleation
Total enucleation
Surgery stated to be ‘de-bulking’
Radical surgery
Surgery, NOS
Unknown if surgery performed death certificate ONLY

Table 4: SEER surgical codes for the Eye. NOS = Not otherwise specified

Statistical Analysis
We computed patient demographic and treatment characteristics using descriptive
statistics such as the ANOVA, chi-squared test and Fisher’s exact test. Univariate
survival analysis was conducted using Kaplan-Meier survival models and log-rank tests.
A Cox proportional hazards regression was used to determine factors affecting overall
survival, including age, sex, race, histology and treatment. Age was dichotomized as
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above or below 60 years, per the recommendation of the International Prognostic Index
model for non-Hodgkin lymphoma.28 Analysis was conducted using RStudio version 1.0
(RStudio, Inc., Boston, MA), with cutoffs for significance defined at p<0.05.

Statement of Exemption and Compliance
This study was compliant with HIPAA, adhered to the tenets of the Declaration of
Helsinki and was approved by the Yale University Institutional Review Board as being
exempt from formal approval due to our work being done using a publicly accessible
anonymized database.

Results
Epidemiology of Orbital Lymphomas
We identified 1504 patients across 6 lymphoma histologic subtypes (Table 5).
Patients had a mean age of 66 years, which did not significantly vary amongst histologic
subtypes. There were slightly more cases of females (53%) diagnosed with OL than
males (800 versus 704, sex-ratio: 1.13). This trend was also observed in every histology
except in the case of MCL, where males accounted for 48/74 cases (64.9%, p = 0.023, see
Table 5). Race did not differ significantly amongst histological subtypes (Table 5), and
1,233 (82%) patients in the cohort were white.

Characteristic
N
Age, mean
(SD), y
Male

Number of Cases (%)
MALT
DLBCL
744 (49.5) 294 (19.5)

FL
204 (13.6)

SLL
143 (9.5)

MCL
74 (4.9)

LPL
45 (3.0)

P Value

65.5
(14.8)

66.4
(17.0)

66.7
(13.7)

66.0
(13.8)

68.8
(11.7)

64.9
(15.5)

0.521

344 (46.2)

140 (47.6)

83 (40.7)

67 (46.9)

48 (64.9)

22 (48.9)

0.023
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Race
White

585 (78.6)

248 (84.4)

174 (85.3)

63 (85.1)

16 (7.8)

121
(84.6)
2 (1.4)

Black

54 (7.3)

18 (6.1)

Other

91 (12.2)

25 (8.5)

Unknown
Surgery
Orbitotom
y with
Biopsy

14 (1.9)

6 (8.1)

2 (4.4)

11 (5.4)

18 (12.6)

4 (5.4)

6 (13.3)

3 (1.0)

3 (1.5)

2 (1.4)

1 (1.4)

0 (0)

284 (38.2)

87 (29.6)

82 (40.2)

21 (14.7)

17 (23.0)

6 (13.3)

41 (5.5)

72 (24.5)

41 (20.1)

87 (60.8)

22 (29.7)

26 (57.8)

419 (56.3)

135 (45.9)

81 (39.7)

35 (24.4)

35 (47.3)

13 (28.9)

479 (64.3)
123 (16.5)

161 (54.8)
182 (61.9)

115 (56.4)
68 (33.3)

99 (30.8)
22 (15.4)

41 (55.4)
30 (40.5)

31 (31.1)
8 (17.8)

Unknown/
Other
No
Surgery
Radiation
Chemotherapy

37 (82.2)

0.052

<0.001

0.005
<0.001

Table 5: Baseline demographic characteristics

Treatment Choices
There were differences in the choice of surgical intervention chosen for patients
with different histological subtypes (Table 5). Radiotherapy was the treatment of choice
in 926 (61.6%) patients with OL. Patients with MALT lymphoma were most likely to
receive radiation therapy (479/745 patients, 64.3%), whereas those with SLL were the
least likely to have radiation therapy (99/143 patients, 30.8%). Chemotherapy was most
commonly administered to patients with DLBCL (182/294 patients, 61.9%) and least
likely given to those with SLL, the nodal form of chronic lymphocytic leukemia (22/143
patients, 15.4%).

Survival and Outcomes
Table 6 provides data on cancer specific survival probabilities amongst various
histologic subtypes. MALT lymphoma conferred the best prognosis (10-year cancer
specific survival [CSS] 90.2%, 95% Confidence Interval [CI] 87.4% – 93.1%) and
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DLBCL conferred the worst prognosis (10-year CSS 68.6%, 95% CI 62.5% – 75.3%)
(p<0.001, log-rank test). Upon pair-wise comparisons, DLBCL conferred a significantly
worse overall survival compared to every other histology, except for MCL and LPL
(p<0.05, log-rank test). Not only did DLBCL confer the worst cancer specific survival,
but also the worst overall survival at 10 years (disease specific survival 44.6%, 95% CI
38.5%-51.7%). Figure 3 shows Kaplan Meier plots of overall and cancer specific survival
amongst the histologic subtypes.
Cox proportional hazards regression showed that older age (Hazard Ratio [HR]: 3.71,
95% Confidence Interval [CI]: 2.94-4.66, p<0.001), male sex (HR: 1.22, 95% CI: 1.0391.441, p = 0.015) and no radiation (HR: 1.72, 95% CI: 1.46-2.02, p<0.001) conferred a
worse prognosis after controlling for the various histologic subtypes (Figure 4). The
effects of chemotherapy and surgery on survival were not significant.

Histology

Survival Percentage (95% Confidence Interval)
1 year
5 year
10 year

MALT Lymphoma

98.9 (98.1 – 99.6)

94.5 (92.7 – 96.4)

90.2 (87.4 – 93.1)

Diffuse Large B Cell
Lymphoma

84.5 (80.3 – 88.9)

72.7 (67.2 – 78.5)

68.6 (62.5 – 75.3)

Follicular
Lymphoma

97.4 (95.2 – 99.7)

88.9 (84.2 – 94.0)

82.7 (76.1 – 89.8)

Small Lymphocytic
Lymphoma

97.2 (94.5 – 99.9)

94.3 (90.5 – 98.2)

88.9 (83.5 – 94.6)

Mantle Cell
Lymphoma

95.9 (91.4 – 100)

82.8 (73.9 – 92.7)

71.0 (59.5 – 84.8)

Lymphoplasmacytic
Lymphoma

100 (100 – 100)

95.2 (89.0 – 100)

84.5 (72.6 – 98.3)

Table 6: Cancer specific survival probabilities by histologic subtype of OL
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Figure 3: Kaplan-Meier plot of overall cumulative survival and cancer specific cumulative survival for
patients with differing histological subtypes
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Figure 4: Cox Proportional Hazards Model of factors associated with overall survival of patients with orbital
lymphoma

Discussion
In the largest cohort study performed on OL, our results demonstrate that
histology is a significant predictor of survival. Large analysis of histology and prognosis
exist for lymphomas in other sites, including the gastrointestinal tract and thyroid,
however, with the exception of the Olsen study, are lacking in the literature on orbital
lymphoma.29–31 To date, this is the first study to compare the long-term survival amongst
the numerous histologic subtypes of OL in the United States. Our results confirm
survival outcomes reported previously in the literature for specific histological
subtypes.10–12,32

The Effect of Disease Histology on Survival
Our finding of the poor prognosis associated with DLBCL mirrors results
reported by Olsen et al, who found DLBCL to confer a 10-year CSS of 41% in their
cohort. However, we demonstrated that in the United States, DLBCL had a 10-year CSS
of 68.6%. Furthermore, Olsen et al observed a 10-year CSS of only 32% for MCL, which
contrasts our reported 10-year CSS of 71%. The decrease in CSS could be due to the
advanced Ann Arbor Stage IV E in their cohort which included 29% DLBCL and 76%
MCL. Due to inherent limitations in the SEER database, our cohort lacked staging
information, thus it was not possible to directly compare survival rates. However, it
should be noted that for other lower grade histologies such as MALT and FL, the vast
majority of diseases documented in the literature are Ann Arbor Stage I E. Therefore,
assuming that the SEER database had a similar distribution of Ann Arbor staged cases as
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the general population amongst patients with low grade histological subtypes of disease,
our results are representative of what is found previously in the literature for these
subtypes of disease. Furthermore, Olsen et al have previously reported in their studies
that disease histologies have the most significant impact on prognosis, regardless of
staging using the Ann Arbor or TNM system.10 Given this observation, our findings are
valuable even in the absence of staging data in our study.

While further prospective confirmatory studies are needed to understand the
mechanistic basis of our results, the comparative survival amongst OL with varying
histology is of clinical relevance. In addition to existing systems for staging, our results
provide additional prognostic information that can be used to guide patient expectations.
DLBCL is a high-grade aggressive malignancy, whereas MALT lymphoma is lowgrade.29,33 In the orbit, these histologic subtypes confer the worst and best prognoses
respectively.
Epidemiological Findings
MALT lymphoma, which portends the best prognosis, presents more commonly
in women and is most commonly found in the fifth decade. These results have been
previously demonstrated in many smaller cohorts.4,5,8,34–36. We found that MCL of the
ocular adnexal region manifests primarily in elderly males, and our findings confirm
other published reports.11,37 Ahmed et al observed no difference in gender on survival in
a subgroup analysis of DLBCL.32 Though our results demonstrated that male gender
independently confers a worse prognosis in OL, this was not a matched controlled study
and thus our results are difficult to generalize to the general population.
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The Effects of Treatments on Survival
We also observed that surgery and chemotherapy did not confer any significant
effect on survival. Since the SEER database did not distinguish the exact type of surgery
performed, it is hard to interpret the lack of survival differences seen in our study. Since
orbitotomy surgeries also included biopsies, it could be possible that the majority of
surgeries performed in our study were only biopsies, which would not confer any effect
on survival. Similarly, the lack of survival difference between patients receiving
chemotherapy versus those who did not could be confounded by the lack of staging data:
it may be possible that patients receiving chemotherapy group had more advanced disease
than those who did not.

Lastly, we also observed that patients who received radiation had better outcomes
compared to those whose radiation status was unknown or negative. Although radiation is
a significant component of effective treatment for OL, our dataset does not provide any
details on the type, extent or frequency of radiation therapy nor the lymphoma staging of
the patients to whom it was administered. Since radiation therapy is typically utilized for
less aggressive stages of orbital lymphoma, our results may be confounded by more
patients with less aggressive lymphoma being treated with radiation.

Study Limitations

There are inherent limitations when using the SEER database. Although the SEER
database is the largest national collection of data on cancers across multiple health
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systems, it has restricted data and does not provide information about clinical course, lab
values, or detailed radiation, type of surgery and chemotherapy information. In the
current database used for this analysis, it was not possible to assess the percentage of
lymphoma from the orbit with conjunctival extension, laterality, and disease recurrence,
which could have been confounding variables. Furthermore, data on AJCC and Ann
Arbor Staging was not available, which is important in disease prognostication. In
addition, over the course of the 41-year study period, our cohort has a higher frequency
of Small Lymphocytic Lymphoma cases compared to other multicenter trials. This may
have occurred due to the variation in histologic classification at the time of diagnosis
spanning four decades. Since histologic data was provided through the database, it is not
possible to confirm the reclassification of our cases in the database according to the
current World Health Organization Classification of Tumors of Hematopoietic and
Lymphoid Tissues.38 However, in the case of rare diseases like OL, performing large
prospective studies is not possible, and hence studies are restricted to retrospective
analysis of large databases or individual cases.39
Conclusion
This SEER database analysis confirms known prognostic information on orbital
lymphoma using the largest cohort of patients to date. Specifically, we demonstrate that
histology is a significant predictor of survival in OL, with DLBCL conferring the worst
prognosis (OS: 44.6% at 10 years) and MALT lymphoma conferring the best prognosis
(OS: 64.9% at 10 years), while fully acknowledging the limitations of the SEER
database. Although age, gender, and the use of radiation treatment are associated with
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differing outcomes, further studies are needed to elucidate the mechanisms governing
these observations.
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